Metrics to compare | SENZA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSENZAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −15.6x | 11.6x | −0.3x | |
PEG Ratio | −5.24 | 4.45 | 0.00 | |
Price/Book | 1.9x | 6.1x | 2.6x | |
Price / LTM Sales | 2.9x | 2.8x | 3.0x | |
Upside (Analyst Target) | - | 68.3% | 56.3% | |
Fair Value Upside | Unlock | −11.7% | 9.8% | Unlock |
SenzaGen AB provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices; and substance based medical devices. In addition, the company offers regulatory toxicity testing services, including skin corrosion, skin irritation, skin sensitization, and skin absorption; and eye irritation, phototoxicity, and cytotoxicity testing services and advisory services to pharma, medial devices, cosmetics, an chemical industries. Further, it provides SenzaGen, a test portfolio to assess toxicity of chemicals, cosmetics, medical devices, drug candidates, and nutrition/food additives. The company offers services through license partners and distributors. It has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. SenzaGen AB was incorporated in 2010 and is headquartered in Lund, Sweden.